Clinical Trials
23 trialsNCT03263936 2025-10-16
Epigenetic Reprogramming in Relapse/Refractory AML
Therapeutic Advances in Childhood Leukemia Consortium
Phase 1 Completed
NCT02269280 2025-08-07
Phase II Decitabine (DAC) Versus Azacitidine (AZA) in Myelodysplastic Syndrome (MDS)
M.D. Anderson Cancer Center
Phase 2 Completed
NCT03066648 2025-05-18
Study of PDR001 and/or MBG453 in Combination With Decitabine in Patients With AML or High Risk MDS
Novartis
Phase 1 Completed
NCT02441803 2024-02-22
Allogeneic Hematopoietic Stem Cell Transplantation (AlloSCT) Initial Salvage Therapy for Induction Failure Acute Myeloid Leukemia (AML)
M.D. Anderson Cancer Center
Phase 2 Completed
NCT01893320 2022-02-09
Study of Vosaroxin and Decitabine in Older Patients With Acute Myeloid Leukemia and High-risk Myelodysplastic Syndrome
M.D. Anderson Cancer Center
Phase 1/2 Completed
NCT01720225 2020-12-24
Decitabine Versus Azacitidine in Myelodysplastic Syndrome Patients With Low and Intermediate-1 Risk
M.D. Anderson Cancer Center
Phase 2 Completed
NCT01786343 2020-04-15
Decitabine for Older or Unfit Patients With Acute Myeloid Leukemia (AML)
M.D. Anderson Cancer Center
Phase 2 Completed
NCT01794702 2019-05-30
Decitabine Followed by Clofarabine, Idarubicin, and Cytarabine in Acute Leukemia
M.D. Anderson Cancer Center
Phase 1/2 Completed
NCT00075010 2018-11-15
Phase I/II Study of Decitabine and Valproic Acid in Relapsed/Refractory Leukemia or Myelodysplastic Syndromes
M.D. Anderson Cancer Center
Phase 1/2 Completed
NCT00903760 2018-11-15
Decitabine and Clofarabine in Higher Risk Myelodysplastic Syndromes (MDS)
M.D. Anderson Cancer Center
Phase 2 Completed
NCT00002831 2018-10-26
Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Chronic Myelogenous or Acute Leukemia
M.D. Anderson Cancer Center
Phase 1/2 Completed
NCT01352650 2018-07-02
Decitabine and Plerixafor in Elderly Acute Myeloid Leukemia (AML)
Weill Medical College of Cornell University
Phase 1 Completed
NCT02084563 2016-11-08
Study of Molecular and Genetic Abnormalities in Patients With Myeloid Neoplasms
Hospital Israelita Albert Einstein
Phase 2 Completed
NCT00778375 2016-07-14
Clofarabine Plus Low-Dose Cytarabine Induction and Decitabine Consolidation in Frontline Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndrome (MDS)
M.D. Anderson Cancer Center
Phase 2 Completed
NCT00479232 2015-09-21
Phase I Trial of Vorinostat (MK-0683, SAHA) in Combination With Decitabine in Patients With AML or MDS (MK-0683-055 EXT1)
Merck Sharp & Dohme LLC
Phase 1 Completed
NCT00882102 2013-09-13
Decitabine and Gemtuzumab Ozogamicin in Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic Syndrome (H-R MDS)
M.D. Anderson Cancer Center
Phase 2 Completed
NCT00003361 2013-06-26
Decitabine in Treating Patients With Myelodysplastic Syndrome
National Cancer Institute (NCI)
Phase 2 Completed
NCT00671697 2013-06-04
Decitabine, Arsenic Trioxide and Ascorbic Acid for Myelodysplastic Syndromes and Acute Myeloid Leukemia
Washington University School of Medicine
Phase 1 Completed
NCT00968071 2013-03-08
Decitabine and Gemtuzumab Ozogamicin in Acute Myelogenous Leukemia and High-risk Myelodysplastic Syndrome
M.D. Anderson Cancer Center
Phase 2 Completed
NCT00002980 2013-02-15
Decitabine in Treating Patients With Melanoma or Other Advanced Cancer
National Cancer Institute (NCI)
Phase 1 Completed
NCT00114257 2013-02-11
Decitabine and FR901228 in Treating Patients With Relapsed or Refractory Leukemia, Myelodysplastic Syndromes, or Myeloproliferative Disorders
National Cancer Institute (NCI)
Phase 1 Completed
NCT00002832 2012-07-30
Decitabine and Peripheral Stem Cell Transplantation in Treating Patients Who Have Relapsed Following Bone Marrow Transplantation for Leukemia, Myelodysplastic Syndrome, or Chronic Myelogenous Leukemia
M.D. Anderson Cancer Center
Phase 1/2 Completed
NCT01378416 2011-07-12
Pharmacokinetic Trial of Decitabine (Dacogen) Administered as a 3-hour Infusion to Patients With Acute Myelogenous Leukemia or Myelodysplastic Syndrome
Eisai Inc.
Phase 1 Completed